

December 2, 2025

The Cost of Waiting: Why Timing and Strategy Matter for Pharma Startup IP

Introduction

Far too often, startup founders treat intellectual property (IP)—especially patents—like an item on a to-do list. “We’ll file once the science is ready,” they say. But here’s the reality: IP isn’t just a box to check off once your breakthrough is complete. Your strategy should begin before your first patent application, and it should be woven into every step of your company’s growth. A thoughtful IP approach isn’t just about protection. It’s about **positioning, leverage, and legacy**. The right timing and strategy can mean the difference between attracting top-tier investors, forging valuable partnerships, and building a company that endures—or missing out entirely.

The Cost of Waiting

Let’s break down the risks. These are mistakes I see again and again:

- **Premature Disclosure:** Founders share details about their technology at conferences, in pitch decks, or on preprint servers before filing a patent. Result? You may lose the ability to patent your invention in many countries.
- **Weak NDAs:** Collaborators sign generic or vague non-disclosure agreements. If the NDA doesn’t hold up, your confidential information could be at risk.
- **Scattershot Patenting:** Patents are filed with no overarching strategy, leaving gaps in protection that investors or competitors will quickly notice.

These aren’t just legal slip-ups—they’re missed opportunities to build lasting value and competitive advantage.

What You Should Be Asking

Before you hit “submit” on any patent application (or allow your attorney to), ask yourself:

- **What IP do we already have—and who owns it?** Is every founder, employee, and collaborator clear on who holds the rights? Are assignments in place?

- **How does our IP align with our funding roadmap?** Will your patent filings support your next round of investment, partnership discussions, or product launch?
- **Are we protecting the platform, not just the product?** Is your patent strategy broad enough to cover future developments, applications, or spin-offs?

IP isn't just a shield—it's your story. A well-crafted portfolio tells investors how you think, how you plan to scale, and how you'll create long-term value.

The Critical First Steps: Timing and Strategy

A. File Early—but Not Too Early

Why Timing Matters:

U.S. patent law (and the laws of most nations worldwide) operates on a “first-to-file” basis. That means the first inventor to file a patent application usually secures the rights, regardless of who first invented it. If you suspect competitors are working on similar technology, speed is essential.

Best Practice:

File as soon as you can clearly and fully describe your invention—when it's both enabled and distinct. Rushing to file before you understand its novelty or utility can lead to weak claims that don't withstand scrutiny.

Critical Mistake to Avoid:

Don't publicly disclose your invention (in journal articles, posters, investor pitches, or even social media) before filing. In most countries, such disclosures will destroy your ability to patent.

B. Use Provisional Applications Wisely

What Is a Provisional Application?

A provisional patent application is a lower-cost way to establish an early filing date. It gives you 12 months to further develop your invention and business plan before filing a full (non-provisional) application.

Caution:

Your provisional must be **detailed enough** to support any claims you'll want to make later. Vague or incomplete provisionals can undermine your rights.

Best Practice:

If your technology is evolving rapidly, update your provisional application with follow-on filings during the year. Ensure every new disclosure or development is covered by the specification. If it's not, file a follow-on provisional!

C. Preserve Your Rights

Ensuring your company truly owns and can fully exploit its inventions requires more than just filing applications. Two key areas often overlooked—collaboration/foreign filings and inventor assignments—can make or break your ability to scale, partner, or exit. Here's how to think strategically and proactively in these areas.

1. Collaboration and Foreign Filings

What's the Issue?

Are you collaborating with academic partners, CROs, or overseas labs? Are you considering filing patents outside the U.S.? International collaboration and global patenting bring tremendous opportunity, but also complex regulatory and legal hurdles.

Best Practice:

Before sharing your invention with any external party—especially those outside your home country—review local laws and your collaboration agreements. Some countries require government approval before filing abroad (e.g., U.S. inventors must obtain a foreign filing license before filing abroad for the first filing). Others may have restrictions on where and how patents can be filed.

- Always use precise, enforceable NDAs tailored to your situation.
- Confirm foreign filing requirements early in the process, ideally before any cross-border disclosure.

Caution:

Failing to comply with these requirements can jeopardize your ability to patent in key markets or expose you to penalties. Inadequate NDAs or unclear collaboration agreements may result in loss of confidentiality or shared ownership, threatening your competitive advantage.

2. Ownership and Assignments

What's the Issue?

Who actually owns the patent rights—the individual inventors, or your company? If IP assignments aren't in place, inventors retain ownership and can act independently, risking disputes or even loss of control over your technology.

Best Practice:

Secure signed IP assignments from all inventors, founders, employees, and key contractors as early as

possible—ideally before patent filings are performed. Make this a standard part of onboarding and project kickoff.

- Use clear, comprehensive agreements that specify all rights are assigned to the company.
- Periodically audit your assignments to ensure no gaps exist, especially as your team grows or changes.

Caution:

Without assignments, inventors may have the legal right to exploit the patent independently—even to license or sell it to competitors. This can create major problems if someone leaves the company, disagrees with your strategy, or is approached by third parties. Investors will flag missing assignments as a significant risk during due diligence.

Real-World Impact: Timing Missteps in Practice

Mistake	Consequence	Solution
Public disclosure before filing	Loss of patent rights in most countries	File before presenting or publishing
Weak provisional application	Limited or invalid claims later	Ensure detailed, enabling disclosure
Failure to secure assignments	Disputes over ownership, risk of lost rights	Obtain signed assignments up front
No portfolio strategy	Gaps in protection, missed investor opportunities	Align IP with business milestones
Neglecting collaboration/foreign filings	Inability to patent in key countries, regulatory penalties	Review foreign filing laws, use strong NDAs

Conclusion

In the fast-moving world of pharmaceutical innovation, timing isn't just important—it's everything. Waiting too long to implement an IP strategy can close doors that are hard (or impossible) to reopen. By understanding the costs of waiting, acting early, and aligning your patent strategy with your business goals, you'll be positioned to build real value and secure your startup's future.

Ready to take control of your IP strategy? Contact us to customize your approach and avoid costly mistakes down the road.

Pharma Startup IP Timing & Strategy Checklist

Step	Action Item	Why It Matters
1	Map Your IP Assets	Know what you have, who owns it, and where gaps exist.
2	Establish Assignments Early	Secure company ownership of all inventions.
3	File Before Public Disclosure	Preserve patent rights in all key markets.
4	Use Provisional Applications Strategically	Buy time to refine your invention and business plan.
5	Update Provisionals as Needed	Capture ongoing developments and improvements.
6	Align IP with Funding Roadmap	Ensure filings support upcoming investment rounds.
7	Protect the Platform	Think beyond the initial product—cover core technologies.
8	Educate Your Team	Train staff on confidentiality and invention disclosure protocols.